ASX - Delayed Quote AUD

Radiopharm Theranostics Limited (RAD.AX)

0.0230

+0.0010

+(4.55%)

At close: 3:29:06 PM GMT+10

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, announced today that it has achieved a key milestone in its ongoing clinical

GlobeNewswire 2 days ago

RADX

RDPTF
RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology

By John Vandermosten, CFA NASDAQ:RADX READ THE FULL RADX RESEARCH REPORT We are initiating coverage of Radiopharm Theranostics Limited (NASDAQ:RADX) and assign a valuation of $12.50 per American Depository Receipt (ADR). This valuation is based on our estimates for successful development, approval and commercialization of RAD101, RAD202 and RAD204 in the United States and developed world.

Zacks Small Cap Research 2 days ago

RADX
Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. To register for one-on-one meetings with management in New York City, interested pa

GlobeNewswire 7 days ago

RADX

RDPTF
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis

Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing transformative oncology radiopharmaceuticals SYDNEY, April 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical n

GlobeNewswire 16 days ago

RADX

RDPTF
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable biodistribution and low uptake in non-target organs, except for the bladder and kidney as expectedTreatment with 177Lu-RAD202 results in a relevant tumor volume reduction and survival benefit, further pronounced with fractionated therapy vs single-dose treatment.These data further support the rationale for the ongoing Phase I therapeutic trial with

GlobeNewswire last month

RADX

RDPTF
Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 2 months ago

RADX

RDPTF
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All brain metastases, regardless of whether they were previously treated with radiation and the tumor of origin, were detected with RAD101, demonstrating a high tumor-to-background ratio.A Phase 2b imaging study to evaluate the diagnostic performance of RAD 101 in individuals with suspected recurrent brain metastases is currently recruiting in

GlobeNewswire 3 months ago

RADX

RDPTF
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus shareholding in Radiopharm increases to 12.16% following the placementThe funds raised will be applied to the development of Radiopharm’s clinical pipeline SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD; NASDAQ:RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceut

GlobeNewswire 4 months ago

RADX

RDPTF
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon meeting clinical milestone targets SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to

GlobeNewswire 4 months ago

RADX

RDPTF
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumorsTen HER2-positive breast cancer patients previously dosed in a Phase 1 diagnostic study demonstrated the safety and biodistribution of 177Lu-RAD202, validating its potential for

GlobeNewswire 4 months ago

RADX

RDPTF
Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No associated capital raisingModest admin & financial compliance overheads SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that American Depositary Shares (“ADSs”) rep

GlobeNewswire 5 months ago

RADX

RDPTF
Radiopharm Theranostics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Radiopharm Theranostics ( ASX:RAD ) Full Year 2024 Results Key Financial Results Net loss: AU$47.9m (loss widened by...

Simply Wall St. 7 months ago

RADTY

RDPTF
Radiopharm Theranostics Non-Executive Director Acquires 430% More Stock

Potential Radiopharm Theranostics Limited ( ASX:RAD ) shareholders may wish to note that the Non-Executive Director...

Simply Wall St. 7 months ago

RADTY

RDPTF
Radiopharm Receives Strategic Investment for up to A$18 million

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The

GlobeNewswire 10 months ago

RDPTF

LNTH

Performance Overview

Return	RAD.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-4.17%	+1.66%
1-Year	-39.47%	+6.97%
3-Year	-87.08%	+17.23%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Radiopharm Theranostics Limited (RAD.AX)

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Radiopharm Theranostics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Radiopharm Theranostics Non-Executive Director Acquires 430% More Stock

Radiopharm Receives Strategic Investment for up to A$18 million

Performance Overview